MLICM
AMLX icon

Metropolitan Life Insurance Company (MetLife)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,899
Closed -$8.23K – 121
2024
Q1 		$8.23K Hold
2,899
– – ﹤0.01% 2194
2023
Q4 		$42.7K Hold
2,899
– – ﹤0.01% 1533
2023
Q3 		$53.1K Hold
2,899
– – ﹤0.01% 1368
2023
Q2 		$62.5K Hold
2,899
– – ﹤0.01% 1296
2023
Q1 		$85.1K Sell
2,899
-251
-8% -$8.72K ﹤0.01% 1089
2022
Q4 		$116K Buy
3,150
+943
+43% +$33.5K 0.01% 972
2022
Q3 		$62.1K Buy
2,207
+1,412
+178% +$35.2K ﹤0.01% 1309
2022
Q2 		$15.3K Hold
795
– – ﹤0.01% 2166
2022
Q1 		$10.2K Buy
+795
New +$18K ﹤0.01% 2233

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AMLX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 2,899 shares — an estimated $8.23K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AMLX in Q1 2022 and held it in 9 quarters. The position peaked at $116K in Q4 2022. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,899 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $8.23K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Amylyx Pharmaceuticals position peaked at $116K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.